Your Health, We Care
On November 17, 2023, the U.S. Food and Drug Administration (FDA) approved Tucatinib (Capivasertib) in combination with Fulvestrant for the treatment of patients with advanced hormone receptor-positive breast cancer.
On November 17, 2023, AstraZeneca’s capivasertib in combination with Faslodex (fulvestrant) was appr···【more】
Recommended：302026-13-01
On June 12, 2023, the New Drug Application (NDA) for capivasertib in combination with fulvestrant, s···【more】
Recommended：292026-13-01
On November 17, 2023, AstraZeneca’s capivasertib in combination with Faslodex (fulvestrant) was approved in the United States for the treatment of adult patients with hormone recep···【more】
Article source：Lucius LaosRelease date：2026-01-13Recommended：30
On June 12, 2023, the New Drug Application (NDA) for capivasertib in combination with fulvestrant, submitted by AstraZeneca, has been accepted for review and granted priority revie···【more】
Article source：Lucius LaosRelease date：2026-01-13Recommended：29
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
